Showing 201-210 of 3494 results for "".
- Free Podcasts on Complete UV Protectionhttps://practicaldermatology.com/news/20120612-free_podcasts_on_complete_uv_protection/2459785/On the new edition of "Healthy Vision with Dr. Val Jones," dermatologist and author Jeanine Downie, MD, and Stephen Cohen, OD, past president of the Arizona Optometric Association, join Dr. Val to talk about the importance of sun protection. Both doctors share tips on steps adults and children can t
- Advanced Dermatology & Cosmetic Surgery (ADCS Clinics) Acquires The Grekin Skin Institutehttps://practicaldermatology.com/news/20140714-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_the_grekin_skin_institute/2459172/ADCS Clinics ("ADCS") announced it has completed the acquisition of The Grekin Skin Institute in Southfield, Michigan, a dermatology practice founded by Dr. Steven Grekin.
- Subliminally Exposed to be Presented at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20131029-subliminally_exposed_to_be_presented_at_cosmetic_surgery_forum/2459426/Based on the New York Times and USA Today best seller, Subliminally Exposed, Dr. Steven Dayan and Valerie Monroe will present at this year's Cosmetic Surgery Fo
- Omalizumab Shows Median 3.1-Year Drug Survival in Chronic Urticariahttps://practicaldermatology.com/news/omalizumab-shows-median-31-year-drug-survival-in-chronic-urticaria/2488414/Omalizumab demonstrated a median drug survival of more than 3 years among patients with chronic urticaria (CU), with successful disease control rather than adverse events emerging as a common reason for treatment discontinuation, according to a systematic review an
- DRESS: Tofacitinib Shows Glucocorticoid-Sparing Potentialhttps://practicaldermatology.com/news/dress-tofacitinib-shows-glucocorticoid-sparing-potential/2488346/Adding tofacitinib to systemic glucocorticoid therapy was associated with reduced glucocorticoid exposure and faster clinical improvement among patients with drug reaction with eosinophilia and systemic symptoms (DRESS), according to a study published online in the
- Analysis: Antiepileptic Drugs Linked to Nearly One-Quarter of Global SJS/TEN Caseshttps://practicaldermatology.com/news/antiepileptic-drugs-linked-to-nearly-one-quarter-of-global-sjsten-cases-meta-analysis-finds/2487988/Antiepileptic drugs (AEDs) account for nearly one-quarter of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) cases reported worldwide, according to a systematic review and meta-analysis in JAMA Dermatology
- Analysis: Topical Corticosteroids Effective for Select Patients With DRESS Syndromehttps://practicaldermatology.com/news/analysis-data-support-topical-corticosteroids-for-select-patients-with-dress-syndrome/2487960/Topical corticosteroids may offer comparable short-term outcomes to systemic corticosteroids for selected hospitalized patients with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, according to a multicenter retrospective cohort study publi
- Analysis: CHL-Fe-based PDT Shows Activity Against Drug-Resistant C. acneshttps://practicaldermatology.com/news/chl-febased-photodynamic-therapy-shows-potent-activity-against-drug-resistant-c-acnes/2485327/Photodynamic therapy (PDT) using sodium iron chlorophyllin (CHL-Fe) and red light achieved consistent bactericidal effects against drug-resistant Cutibacterium acnes (C. acnes) strains in vitro, according to new study finding
- Hydrocolloid Dressings After Mohs Surgery Yield No Aesthetic Advantage: Studyhttps://practicaldermatology.com/news/hydrocolloid-dressings-after-mohs-surgery-yield-no-aesthetic-advantage-study/2484049/Hydrocolloid dressings (HCDs) and daily petroleum ointment following excisional dermatologic surgery did not perform differently in terms of scar appearance or surgical complications, according to a new trial. The randomized,
- Analysis: New Biologics Account for 70% of Increased Medicare Dermatology Drug Spendinghttps://practicaldermatology.com/news/analysis-new-biologics-account-for-70-of-increased-medicare-dermatology-drug-spending/2475722/Spending on dermatology-related drugs under Medicare Part D nearly quadrupled between 2013 and 2022, with specialty medications (including biologics) responsible for the vast majority of that increase, according to a new study.